These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3755540)

  • 1. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
    Hock CE; Lefer AM
    Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia.
    Bitterman H; Lefer DJ; Lefer AM
    Proc Soc Exp Biol Med; 1987 Jul; 185(3):262-6. PubMed ID: 3037554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia.
    Hock CE; Brezinski ME; Lefer AM
    Eur J Pharmacol; 1986 Mar; 122(2):213-9. PubMed ID: 3011442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
    Hock CE; Phillips GR; Lefer AM
    Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia.
    Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
    Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
    Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Limitation of the area of necrosis induced by quinacrine after coronary occlusion in the dog].
    Ambrosio G; Bigazzi MC; Tritto I; Focaccio A; Brigante F; Migliaccio C; Chiariello M
    G Ital Cardiol; 1985 Dec; 15(12):1139-46. PubMed ID: 3835093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved lactate extraction in dogs with coronary artery ligation following administration of a thromboxane synthetase inhibitor.
    Eddy LJ; Oei HH; Glenn TM
    Res Commun Chem Pathol Pharmacol; 1983 Jan; 39(1):87-97. PubMed ID: 6682567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction.
    Hock CE; Ribeiro LG; Lefer AM
    Am Heart J; 1985 Feb; 109(2):222-8. PubMed ID: 2981461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat.
    Smith EF; Egan JW; Goodman FR; Zimmerman MB; Webb RL; Ribeiro LG
    Pharmacology; 1988; 37(4):254-63. PubMed ID: 2973611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ischemia-induced phospholipase activation by quinacrine protects jeopardized myocardium in rats with coronary artery occlusion.
    Chiariello M; Ambrosio G; Cappelli-Bigazzi M; Nevola E; Perrone-Filardi P; Marone G; Condorelli M
    J Pharmacol Exp Ther; 1987 May; 241(2):560-8. PubMed ID: 3572813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
    Lefer AM; Mentley R; Sun JZ
    Circ Res; 1988 Sep; 63(3):621-7. PubMed ID: 3136950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion.
    Maclean D; Fishbein MC; Braunwald E; Maroko PR
    J Clin Invest; 1978 Mar; 61(3):541-51. PubMed ID: 641137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective actions of propyl gallate, a lipoxygenase inhibitor, on the ischemic myocardium.
    Leprán I; Lefer AM
    Circ Shock; 1985; 15(2):79-88. PubMed ID: 3919959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusion.
    Smith EF; Egan JW; Griswold DE
    Pharmacology; 1989; 38(5):298-309. PubMed ID: 2527373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of KW-3049, a new 1,4-dihydropyridine calcium antagonist, on the reduction of myocardial creatine kinase activity and high-energy phosphate content in rats subjected to coronary artery ligation.
    Karasawa A; Kubo K
    J Pharmacobiodyn; 1988 Nov; 11(11):722-9. PubMed ID: 3236204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the extent of ischemic damage and the effect of the calcium antagonist, verapamil following coronary artery ligation in the rat.
    Markham A; Morgan RM; Sweetman AJ
    Methods Find Exp Clin Pharmacol; 1990 Sep; 12(7):467-72. PubMed ID: 2087146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
    Toki Y; Hieda N; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
    Arzneimittelforschung; 1988 Feb; 38(2):224-7. PubMed ID: 3370068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.